Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
39
BBH Quote, Financials, Valuation and Earnings
Last price:
$158.60
Seasonality move
:
1.55%
Day range:
$157.08 - $159.62
52-week range:
$151.35 - $183.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
29K
Avg. volume:
11.6K
1-year change:
0.05%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
$158.56 | -- | -- | -- | $1.25 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$26.98 | -- | -- | -- | $0.13 | 1.66% | -- |
|
IHF
iShares US Healthcare Providers ETF
|
$48.08 | -- | -- | -- | $0.10 | 0.86% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.22 | -- | -- | -- | $0.01 | 0.05% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$82.67 | -- | -- | -- | $0.22 | 0.93% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$29.44 | -- | -- | -- | $0.06 | 0.68% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | 1.127 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | 1.288 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.832 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 1.335 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
VanEck Biotech ETF vs. Competitors
-
Which has Higher Returns BBH or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About BBH or FTXH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe VanEck Biotech ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is BBH or FTXH More Risky?
VanEck Biotech ETF has a beta of 0.727, which suggesting that the stock is 27.303% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock BBH or FTXH?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.66% to investors and pays a quarterly dividend of $0.13 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or FTXH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns BBH or IHF?
iShares US Healthcare Providers ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat iShares US Healthcare Providers ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- IHFiShares US Healthcare Providers ETF-- -- -- -
What do Analysts Say About BBH or IHF?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare Providers ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than iShares US Healthcare Providers ETF, analysts believe VanEck Biotech ETF is more attractive than iShares US Healthcare Providers ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 IHFiShares US Healthcare Providers ETF0 0 0 -
Is BBH or IHF More Risky?
VanEck Biotech ETF has a beta of 0.727, which suggesting that the stock is 27.303% less volatile than S&P 500. In comparison iShares US Healthcare Providers ETF has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.516%.
-
Which is a Better Dividend Stock BBH or IHF?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0%. iShares US Healthcare Providers ETF offers a yield of 0.86% to investors and pays a quarterly dividend of $0.10 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. iShares US Healthcare Providers ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or IHF?
VanEck Biotech ETF quarterly revenues are --, which are smaller than iShares US Healthcare Providers ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than iShares US Healthcare Providers ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while iShares US Healthcare Providers ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for iShares US Healthcare Providers ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- IHFiShares US Healthcare Providers ETF-- -- -- --
-
Which has Higher Returns BBH or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBH or PBE?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe VanEck Biotech ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBH or PBE More Risky?
VanEck Biotech ETF has a beta of 0.727, which suggesting that the stock is 27.303% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.07%.
-
Which is a Better Dividend Stock BBH or PBE?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or PBE?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBH or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About BBH or PJP?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe VanEck Biotech ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is BBH or PJP More Risky?
VanEck Biotech ETF has a beta of 0.727, which suggesting that the stock is 27.303% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.580, suggesting its less volatile than the S&P 500 by 42.037%.
-
Which is a Better Dividend Stock BBH or PJP?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0%. Invesco Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.22 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or PJP?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns BBH or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About BBH or RSPH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe VanEck Biotech ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is BBH or RSPH More Risky?
VanEck Biotech ETF has a beta of 0.727, which suggesting that the stock is 27.303% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.863, suggesting its less volatile than the S&P 500 by 13.707%.
-
Which is a Better Dividend Stock BBH or RSPH?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.68% to investors and pays a quarterly dividend of $0.06 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or RSPH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
